NKTR-118
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Opioid-induced constipation (OIC) and other gastrointestinal (GI) symptoms of opioid-induced bowel dysfunction (OIBD…
This randomized, double‐blind, placebo‐controlled, ascending‐dose, crossover study evaluated single oral doses of naloxegol (NKTR…
Opioid‐induced constipation (OIC) is the most common and often a treatment‐limiting adverse event (AE) of opioid therapy for…
Introduction: Adverse effects frequently limit the therapeutic benefits of opioid analgesics. Gastrointestinal adverse effects…
NKTR-118, a novel PEGylated naloxol conjugate, is an oral, once daily investigational agent in development for treatment of…
AstraZeneca has signed a licensing deal with Nektar Therapeutics to develop and market the latter’s two drugs, NKTR-118 and NKTR…